v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2023   544,912,215      
Balance at beginning of period at Dec. 31, 2023 $ 247,949 $ 545 $ 1,844,988 $ (1,597,769) $ 185
Increase (Decrease) in Stockholders' Equity          
Net loss (55,390)     (55,390)  
Other comprehensive income (loss) (448)       (448)
Foreign currency translation adjustments (10)       (10)
Issuance of common stock and pre-funded warrant to purchase common stock in public offering, net of issuance costs of $9,000 (in shares)   41,999,998      
Issuance of common stock and pre-funded warrant to purchase common stock in public offering, net of issuance costs of $9,000 141,000 $ 42 140,958    
Issuances of common stock in connection with exercise of warrants (in shares)   37,640      
Issuance of common stock in connection with exercise of warrants 49   49    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   4,211,493      
Stock-based compensation related to issuances of common stock and options in exchange for services 6,749 $ 4 6,745    
Issuance of common stock under equity plans (in shares)   2,462      
Issuances of common stock under equity plans 92   92    
Stock-based compensation for equity-based awards to employees and directors 4,877   4,877    
Balance at end of period (in shares) at Mar. 31, 2024   591,163,808      
Balance at end of period at Mar. 31, 2024 344,868 $ 591 1,997,709 (1,653,159) (273)
Balance at beginning of period (in shares) at Dec. 31, 2023   544,912,215      
Balance at beginning of period at Dec. 31, 2023 247,949 $ 545 1,844,988 (1,597,769) 185
Increase (Decrease) in Stockholders' Equity          
Net loss (122,773)        
Foreign currency translation adjustments (31)        
Balance at end of period (in shares) at Jun. 30, 2024   601,048,108      
Balance at end of period at Jun. 30, 2024 306,695 $ 601 2,027,173 (1,720,542) (537)
Balance at beginning of period (in shares) at Mar. 31, 2024   591,163,808      
Balance at beginning of period at Mar. 31, 2024 344,868 $ 591 1,997,709 (1,653,159) (273)
Increase (Decrease) in Stockholders' Equity          
Net loss (67,383)     (67,383)  
Other comprehensive income (loss) (243)       (243)
Foreign currency translation adjustments (21)       (21)
Offering expenses (271)   (271)    
Issuances of common stock in connection with exercise of warrants (in shares)   281,211      
Issuance of common stock in connection with exercise of warrants 365   365    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   1,916      
Stock-based compensation related to issuances of common stock and options in exchange for services 16 $ 1 15    
Issuance of common stock under equity plans (in shares)   9,400,121      
Issuances of common stock under equity plans 16,373 $ 9 16,364    
Stock-based compensation for equity-based awards to employees and directors 12,625   12,625    
Employee stock purchases (in shares)   201,052      
Employee stock purchases 366   366    
Balance at end of period (in shares) at Jun. 30, 2024   601,048,108      
Balance at end of period at Jun. 30, 2024 306,695 $ 601 2,027,173 (1,720,542) (537)
Balance at beginning of period (in shares) at Dec. 31, 2024   606,387,666      
Balance at beginning of period at Dec. 31, 2024 280,320 $ 606 2,051,794 (1,772,341) 261
Increase (Decrease) in Stockholders' Equity          
Net loss (19,835)     (19,835)  
Other comprehensive income (loss) 55       55
Foreign currency translation adjustments (12)       (12)
Exercise of Pre-Funded Warrant (in shares)   30,369,830      
Exercise of Pre-Funded Warrant 31 $ 31      
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   4,913      
Stock-based compensation related to issuances of common stock and options in exchange for services 15   15    
Issuance of common stock under equity plans (in shares)   155,349      
Issuances of common stock under equity plans 256   256    
Stock-based compensation for equity-based awards to employees and directors 7,408   7,408    
Balance at end of period (in shares) at Mar. 31, 2025   636,917,758      
Balance at end of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Balance at beginning of period (in shares) at Dec. 31, 2024   606,387,666      
Balance at beginning of period at Dec. 31, 2024 280,320 $ 606 2,051,794 (1,772,341) 261
Increase (Decrease) in Stockholders' Equity          
Net loss (36,210)        
Foreign currency translation adjustments (8)        
Balance at end of period (in shares) at Jun. 30, 2025   637,849,739      
Balance at end of period at Jun. 30, 2025 259,531 $ 638 2,067,327 (1,808,551) 117
Balance at beginning of period (in shares) at Mar. 31, 2025   636,917,758      
Balance at beginning of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Increase (Decrease) in Stockholders' Equity          
Net loss (16,375)     (16,375)  
Other comprehensive income (loss) (191)       (191)
Foreign currency translation adjustments 4       4
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   5,540      
Stock-based compensation related to issuances of common stock and options in exchange for services 26   26    
Issuance of common stock under equity plans (in shares)   509,072      
Issuances of common stock under equity plans 591 $ 1 590    
Stock-based compensation for equity-based awards to employees and directors 6,738   6,738    
Employee stock purchases (in shares)   417,369      
Employee stock purchases 500   500    
Balance at end of period (in shares) at Jun. 30, 2025   637,849,739      
Balance at end of period at Jun. 30, 2025 $ 259,531 $ 638 $ 2,067,327 $ (1,808,551) $ 117